Brokerages are optimistic about Piramal Pharma’s growth. Jefferies and Motilal Oswal have given it a ‘buy’ rating and with a target price to ₹260.
Brokerages are optimistic about Piramal Pharma’s growth. Jefferies and Motilal Oswal have given it a ‘buy’ rating and with a target price to ₹260.